Eiger BioPharmaceuticals (STU:72C) Accounts Payable: €1.94 Mil (As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:72C Eiger BioPharmaceuticals Inc STU:72C
10 GF Score
Price €6.18
View Full Analysis

What is Eiger BioPharmaceuticals Accounts Payable?

Eiger BioPharmaceuticals STU:72C 10 Accounts Payable is €1.94 Mil as of Dec. 2023. GuruFocus rates STU:72C with a GF Score™ of 10/100.

Eiger BioPharmaceuticals's Accounts Payable for the quarter that ended in Dec. 2023 was €1.94 Mil.

Eiger BioPharmaceuticals's quarterly Accounts Payable declined from Dec. 2022 (€8.47 Mil) to Jun. 2023 (€4.57 Mil) and declined from Jun. 2023 (€4.57 Mil) to Dec. 2023 (€1.94 Mil).

Eiger BioPharmaceuticals's annual Accounts Payable increased from Dec. 2021 (€6.87 Mil) to Dec. 2022 (€8.47 Mil) but then declined from Dec. 2022 (€8.47 Mil) to Dec. 2023 (€1.94 Mil).

Eiger BioPharmaceuticals Accounts Payable Related Terms

Eiger BioPharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Eiger BioPharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eiger BioPharmaceuticals Accounts Payable Chart

Eiger BioPharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.77 3.81 6.87 8.47 1.94

Eiger BioPharmaceuticals Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.41 8.47 4.57 1.94 3.49
STU:72C
10GF Score
Eiger BioPharmaceuticals Inc STU:72C
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eiger BioPharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €1.94 Mil mean?
Eiger BioPharmaceuticals (STU:72C) has a Accounts Payable of €1.94 Mil as of Dec. 2023. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Eiger BioPharmaceuticals and its competitors.
Is Eiger BioPharmaceuticals' Accounts Payable too high?
Eiger BioPharmaceuticals' current Accounts Payable is €1.94 Mil. Overall, Eiger BioPharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Eiger BioPharmaceuticals' Accounts Payable compare to EDSA and SIGY?
Eiger BioPharmaceuticals' Accounts Payable of €1.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Eiger BioPharmaceuticals and its competitors. Eiger BioPharmaceuticals's current Accounts Payable is €1.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiger BioPharmaceuticals stock overvalued right now?
Eiger BioPharmaceuticals (STU:72C) has a current Accounts Payable of €1.94 Mil. The current Accounts Payable is €1.94 Mil. Eiger BioPharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Eiger BioPharmaceuticals (STU:72C), the current Accounts Payable is €1.94 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eiger BioPharmaceuticals Business Description

Address 2155 Park Boulevard, Palo Alto, CA, USA, 94306
Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
10GF Score

Get the complete analysis for STU:72C

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.18
Price